Population characteristics
| Characteristic . | N (%)/median [IQR] . | P∗ . | |
|---|---|---|---|
| CIBMTR cohort . | DRST cohort . | ||
| Number of patients | 2025 | 796 | |
| Patient age (y) | 57 (44-65) | 56 (47-64) | .26 |
| Disease status | .40 | ||
| CR 1 | 1587 (78) | 636 (80) | |
| CR ≥2 | 438 (22) | 160 (20) | |
| Cytogenetics (SWOG) | <.001 | ||
| Good | 121 (6) | 5 (1) | |
| Intermediate | 504 (25) | 712 (89) | |
| Poor | 144 (7) | 79 (10) | |
| Unknown | 1256 (62) | ||
| HCT-CI score | —† | ||
| 0 | 506 (25) | 215 (27) | |
| 1-2 | 687 (34) | — | |
| ≥3 | 832 (41) | — | |
| >0‡ | — | 581 (73) | |
| Conditioning | <.001 | ||
| RIC/nonmyeloablative | 836 (41) | 589 (74) | |
| MAC | 1189 (59) | 207 (26) | |
| GVHD prophylaxis | <.001 | ||
| Tac based | 1791 (88) | 55 (7) | |
| CSA based | 234 (12) | 712 (93) | |
| Other | — | 29 (4) | |
| Donor age (y) | 28 (23-35) | 31 (25-39) | <.001 |
| Recipient CMV serostatus§ | <.001 | ||
| Seronegative | 655 (33) | 328 (41) | |
| Seropositive | 1358 (67) | 463 (58) | |
| Graft source | <.001 | ||
| Peripheral blood | 1738 (86) | 768 (96) | |
| Bone marrow | 287 (14) | 28 (4) | |
| In vivo T-cell depletion | <.001 | ||
| ATG or campath | 802 (40) | 628 (79) | |
| Neither | 1221 (60) | 168 (21) | |
| F donor to M recipient | 230 (11) | 62 (8) | |
| Year | <.001 | ||
| 2005-2009 | 0 (0) | 60 (8) | |
| 2010-2013 | 1129 (56) | 161 (20) | |
| 2014-2017 | 896 (44) | 575 (72) | |
| DQ | .005 | ||
| Matched | 1918 (95) | 774 (97) | |
| Mismatched | 107 (5) | 22 (3) | |
| KIR haplotype | .94 | ||
| AA | 649 (32) | 257 (32) | |
| Bx | 1376 (68) | 539 (68) | |
| Characteristic . | N (%)/median [IQR] . | P∗ . | |
|---|---|---|---|
| CIBMTR cohort . | DRST cohort . | ||
| Number of patients | 2025 | 796 | |
| Patient age (y) | 57 (44-65) | 56 (47-64) | .26 |
| Disease status | .40 | ||
| CR 1 | 1587 (78) | 636 (80) | |
| CR ≥2 | 438 (22) | 160 (20) | |
| Cytogenetics (SWOG) | <.001 | ||
| Good | 121 (6) | 5 (1) | |
| Intermediate | 504 (25) | 712 (89) | |
| Poor | 144 (7) | 79 (10) | |
| Unknown | 1256 (62) | ||
| HCT-CI score | —† | ||
| 0 | 506 (25) | 215 (27) | |
| 1-2 | 687 (34) | — | |
| ≥3 | 832 (41) | — | |
| >0‡ | — | 581 (73) | |
| Conditioning | <.001 | ||
| RIC/nonmyeloablative | 836 (41) | 589 (74) | |
| MAC | 1189 (59) | 207 (26) | |
| GVHD prophylaxis | <.001 | ||
| Tac based | 1791 (88) | 55 (7) | |
| CSA based | 234 (12) | 712 (93) | |
| Other | — | 29 (4) | |
| Donor age (y) | 28 (23-35) | 31 (25-39) | <.001 |
| Recipient CMV serostatus§ | <.001 | ||
| Seronegative | 655 (33) | 328 (41) | |
| Seropositive | 1358 (67) | 463 (58) | |
| Graft source | <.001 | ||
| Peripheral blood | 1738 (86) | 768 (96) | |
| Bone marrow | 287 (14) | 28 (4) | |
| In vivo T-cell depletion | <.001 | ||
| ATG or campath | 802 (40) | 628 (79) | |
| Neither | 1221 (60) | 168 (21) | |
| F donor to M recipient | 230 (11) | 62 (8) | |
| Year | <.001 | ||
| 2005-2009 | 0 (0) | 60 (8) | |
| 2010-2013 | 1129 (56) | 161 (20) | |
| 2014-2017 | 896 (44) | 575 (72) | |
| DQ | .005 | ||
| Matched | 1918 (95) | 774 (97) | |
| Mismatched | 107 (5) | 22 (3) | |
| KIR haplotype | .94 | ||
| AA | 649 (32) | 257 (32) | |
| Bx | 1376 (68) | 539 (68) | |
CMV, cytomegalovirus; CR1, first complete remission; CR ≥2, second or later CR; CsA, cyclosporine A; DQ, HLA-DQB1 match; F, female; HCT-CI, HCT-specific comorbidity index; M, male; MAC, myeloablative conditioning; RIC, reduced-intensity conditioning; SWOG, Southwestern Oncology Group; Tac, tacrolimus.
P value from the χ2 statistic for categorical variables and the Wilcoxon test for continuous variables.
Not calculated because of absent information in 1 cohort.
Patients in the DRST cohort were grouped based on absence vs presence of HCT-CI comorbidities.
In the DRST cohort, recipient CMV serostatus was missing for 5 patients (<1%).